Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire

NCT00147628

Last updated date
Study Location
Pfizer Investigational Site
Huntsville, Alabama, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Impotence
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Documented clinical diagnosis of erectile dysfunction, defined by a score of less than or equal to 25 on the Erectile Dysfunction domain of the International Index of Erectile Function

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects who have been treated with more than 6 doses of sildenafil or any other
phosphodiesterase type 5 inhibitor

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

ImpotenceEvaluation of the Index of Sexual Life Questionnaire
NCT00245596
  1. Amphion-Les-Bains,
  2. Bordeaux,
  3. La Rochelle,
  4. Lille,
  5. Lyon Cedex 03,
  6. Lyon,
  7. PARIS Cedex 13,
  8. Paris,
  9. Saint-Emilion,
  10. Thionville,
  11. Toulouse,
Male
18 Years+
years
MULTIPLE SITES
ImpotenceA Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses
NCT00273416
  1. Oslo,
  2. Belfast, Northern Ireland
Male
18 Years+
years
MULTIPLE SITES
ImpotenceAssessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
NCT00141349
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Mesa, Arizona
  5. Mesa, Arizona
  6. Mesa, Arizona
  7. Tempe, Arizona
  8. Beverly Hills, California
  9. San Bernardino, California
  10. Torrance, California
  11. Waterbury, Connecticut
  12. Aventura, Florida
  13. Pembroke Pines, Florida
  14. St. Petersburg, Florida
  15. West Palm Beach, Florida
  16. Evansville, Indiana
  17. Fort Wayne, Indiana
  18. Jeffersonville, Indiana
  19. Metairie, Louisiana
  20. Metairie, Louisiana
  21. Milford, Massachusetts
  22. Kansas City, Missouri
  23. New Brunswick, New Jersey
  24. Albany, New York
  25. Endwell, New York
  26. New York, New York
  27. Raleigh, North Carolina
  28. Raleigh, North Carolina
  29. Winston-Salem, North Carolina
  30. Beachwood, Ohio
  31. Cincinnati, Ohio
  32. Cleveland, Ohio
  33. Bryan, Texas
  34. Sugar Land, Texas
  35. Salt Lake City, Utah
  36. West Jordan, Utah
  37. Norfolk, Virginia
  38. Richmond, Virginia
  39. Milwaukee, Wisconsin
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire
Official Title  ICMJE A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction
Brief Summary To evaluate the effectiveness of sildenafil on erectile function and intercourse satisfaction in men with ED as well as to validate the new Sexual Experience Questionnaire which incorporates functional and emotional elements of a man's sexual experience into one comprehensive questionnaire.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Impotence
Intervention  ICMJE
  • Drug: sildenafil citrate
  • Drug: placebo for sildenafil citrate
Study Arms  ICMJE Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 27, 2011)
209
Original Enrollment  ICMJE
 (submitted: September 4, 2005)
180
Actual Study Completion Date  ICMJE September 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Documented clinical diagnosis of erectile dysfunction, defined by a score of less than or equal to 25 on the Erectile Dysfunction domain of the International Index of Erectile Function

Exclusion Criteria:

  • Subjects who have been treated with more than 6 doses of sildenafil or any other phosphodiesterase type 5 inhibitor
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00147628
Other Study ID Numbers  ICMJE A1481236
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP